Endometrial Endometrioid Adenocarcinoma
Information
- Disease name
- Endometrial Endometrioid Adenocarcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04214067 | Active, not recruiting | Phase 3 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | April 9, 2020 | February 1, 2025 |
| NCT02020707 | Active, not recruiting | Phase 1 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | February 24, 2014 | June 30, 2025 |
| NCT03914612 | Active, not recruiting | Phase 3 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | July 16, 2019 | May 10, 2024 |
| NCT04972682 | Completed | N/A | [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer | July 1, 2021 | April 15, 2024 |
| NCT02728258 | Completed | Phase 2 | Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | September 16, 2016 | February 14, 2020 |
| NCT00478426 | Completed | Phase 2 | Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | April 30, 2007 | February 12, 2019 |
| NCT05950464 | Recruiting | Phase 1 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | December 18, 2023 | April 30, 2026 |
| NCT03422198 | Recruiting | Phase 3 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer | January 30, 2018 | October 31, 2029 |
| NCT05112601 | Recruiting | Phase 2 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | June 2, 2022 | April 30, 2026 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT04049227 | Unknown status | Early Phase 1 | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | August 12, 2019 | July 1, 2023 |
| NCT03677024 | Withdrawn | N/A | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk Endometrial Carcinomas | February 6, 2020 | October 7, 2021 |